Is that criticism justified?Ī: I don’t think so. Q: Your app makes it fun and easy to trade, but that’s something you get criticism for, both on Wall Street and from regulators. We think there’s a lot more we can still do to serve the individual investor. Individual investors have undoubtedly seen a resurgence over the past few years, and Robinhood has been part of that story. Is the IPO a sign the company has turned the corner?Ī: I think it’s an amazing milestone, and it’s really a celebration of the individual investor. Q: This year started off rocky for Robinhood with the GameStop saga. This interview has been edited for clarity and for length. But Tenev said he wants his app to encourage everyone to profit from the stock market, not just the elite. It also forced Robinhood to temporarily bar its customers from making some GameStop trades, after it suddenly had to post much more in collateral to its clearinghouses that process its trades.Ĭritics say the company based in Menlo Park, California, encourages unsophisticated investors to make dangerous bets by making it seem too much like a game. The mania led to big losses for some hedge funds, multiple halts in trading for stocks and congressional hearings asking who was getting hurt. Such investors are getting their first chance to grow their wealth, after years of falling further behind stock-owning households, but they also have been criticized for making too many risky trades with their newfound app.Įarly this year, they almost singlehandedly sent GameStop and a group of other “meme stocks” to heights professional investors called dangerously irrational. Tenev, who founded Robinhood with fellow Stanford graduate Baiju Bhatt in 2013, also said he accepts how his company has become synonymous with the boom in trading by smaller-pocketed and novice investors, for both good and ill. That covers everything from depositing paychecks to paying bills to splitting payments with friends. In an interview with The Associated Press, Tenev said he wants Robinhood to be the only app that people use on their phones for money. But while the IPO is a milestone, it’s not a culmination, according to CEO Vlad Tenev. Shares of Robinhood Markets are set to begin trading on the Nasdaq Thursday, a highly anticipated initial offering by the company that’s drawn a new generation of investors into the market and forced the industry to stop charging fees for trading. Now its sights are on the rest of the financial industry. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.NEW YORK (AP) - Robinhood has already changed how people trade stocks and who’s doing it. The Zacks Consensus EPS estimate remained stagnant within the past month. It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). Our system takes these estimate changes into account and delivers a clear, actionable rating model. We developed the Zacks Rank to capitalize on this phenomenon. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Recent revisions tend to reflect the latest near-term business trends. These totals would mark changes of +23.8% and +18359.92%, respectively, from last year.Īny recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$6.37 per share and revenue of $221.15 million. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.2 million, up 1901.88% from the year-ago period. On that day, CRISPR Therapeutics AG is projected to report earnings of -$2.18 per share, which would represent year-over-year growth of 9.17%. Heading into today, shares of the company had gained 0.81% over the past month, outpacing the Medical sector's loss of 1.53% and lagging the S&P 500's gain of 2.65% in that time.ĬRISPR Therapeutics AG will be looking to display strength as it nears its next earnings release. At the same time, the Dow added 1.06%, and the tech-heavy Nasdaq gained 4.62%. This move lagged the S&P 500's daily gain of 0.71%. In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $57.75, marking a -0.81% move from the previous day.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |